康莱特注射液配合化疗治疗晚期非小细胞肺癌的临床观察  

Chemotherapy combined with Kanglaite in treatment of advanced non-small cell lung cancer

作　　者：廖国清[1] 王贵徽 刘鹏辉[1] 王红梅[1] 曲怡梅[1] 解国清[1] 

机构地区：[1]解放军总医院第二附属医院肿瘤科 [2]昆明市77225部队医院

出　　处：《实用肿瘤杂志》2009年第6期595-598,共4页Journal of Practical Oncology

摘　　要：目的比较康莱特注射液加化疗与单独化疗治疗晚期非小细胞肺癌患者的疗效和毒副反应。方法将288例经病理组织学确诊的晚期非小细胞肺癌患者分成2组,每组144例。治疗组:NP方案(诺维本+顺铂)+康莱特注射液200 mL,每天1次,连用20天;对照组:单用NP方案。完成2周期后作疗效评价。结果治疗组有效率44.4%,对照组33.3%,两组差异无统计学意义(P>0.05)。治疗组血液毒副反应和消化道反应低于对照组,两组差异有统计学意义(P<0.05)。生活质量评分治疗组高于对照组,两组间差异有统计学意义(P<0.01)。治疗组化疗后较化疗前比较,CD 3比例略有上升,CD 4和CD 4/CD 8明显上升,CD 8明显下降(均P<0.05)。结论康莱特注射液与化疗联合治疗晚期非小细胞肺癌可降低化疗对患者的毒副反应,提高细胞免疫功能,改善患者的生活质量。Objective To evaluate the efficacy and adverse effect of chemotherapy combined with Kanglaite for non- small cell lung cancer （NSCLC）. Methods Two hundred and eighty-eight NSCLC patients were divided into treatment and control groups with 144 patients in each. All patients underwent navelbine plus platinum protocol of chemotherapy （NP）,in treatment group Kanglaite injection 200 mL was also given intravenously a day for 20 days. Results The response rate in treatment group was 44.4%,that of control group was 33.3%（P〉0.05）; the rate of adverse effect in the treatment group was also lower than that in control group （P〈0.05）. The improvement in Karnofsky scores in the treatment group was higher than tant in control group （P〈0.01）. Of 144 cases after treatment with Kanglaite, CD4 count was increased,CD8 decreased （P〈0. 05） and the ratio of CD4/CD8 was increased significantly. Conclusion Chemotherapy combined with Kanglaite can reduce adverse effect of chemotherapy,enhance immune functions and improve the quality of life of patients with advanced non-small cell lung cancer.

关 键 词：癌 非小细胞肺/中西医结合疗法 肺肿瘤/中西医结合疗法 顺铂/治疗应用 药物疗法 联合 薏苡仁/治疗应用 长春碱/治疗应用 注射剂 

分 类 号：R734.2[医药卫生—肿瘤]